EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramond, A.
Right arrow Articles by Joyeux-Faure, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramond, A.
Right arrow Articles by Joyeux-Faure, M.
Experimental Biology and Medicine 233:76-83 (2008)
doi: 10.3181/0706-RM-152
© 2008 Society for Experimental Biology and Medicine

ORIGINAL RESEARCH ARTICLE

Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts

Amandine Ramond*,{dagger}, Eugénie Sartorius*,{dagger}, Mireille Mousseau{ddagger}, Christophe Ribuot*,{dagger} and Marie Joyeux-Faure*,{dagger},1

* Laboratoire HP2, Hypoxie Physio-Pathologie Respiratoire et Cardiovasculaire, EA 3745, Faculté de Medecine-Pharmacie, Universite Grenoble I, France; {dagger} ERI 0017, Inserm, France; and {ddagger} Department of Oncology and Haematology, CHU de Grenoble, France

To whom requests for reprints should be addressed at 1 Laboratoire HP2, Faculté de Pharmacie, Domaine de la Merci, 38706 La Tronche, France. E-mail: Marie. Faure{at}ujf-grenoble.fr

The use of chemotherapeutic agents, such as anthracycline or trastuzumab, in oncology is limited by their cardiac toxicity. Recent experimental studies suggest that recombinant human erythropoietin (rhEPO) can be considered as a protective agent because its administration protects against cardiac ischemic injury, improving functional recovery, and reducing cell death. The aim of this study was to investigate whether pretreatment by rhEPO protects against acute cardiotoxicity induced by doxorubicin and trastuzumab, using the isolated rat heart model. Rats were treated with rhEPO (5000 IU/kg, intraperitoneally [ip]) or vehicle. One hour later, hearts were isolated and retrogradely perfused at constant flow. Following 20 mins of stabilization, hearts were perfused for 60 mins with modified-Krebs solution containing 6 mg/l doxorubicin or 10 mg/l trastuzumab. Hearts receiving doxorubicin were paced; those receiving trastuzumab were unpaced. Control hearts were perfused with modified-Krebs solution only. Doxorubicin exposure decreased left ventricular developed pressure (LVDP; approximately –40% of baseline) and increased end diastolic pressure (EDP; approximately +390% of baseline) and coronary perfusion pressure (CPP; approximately +70% of baseline). Incidence of ventricular tachycardia or fibrillation (VT/VF) was also significantly enhanced (86% vs. 0% in control group). Trastuzumab exposure increased CPP and EDP (approximately +70% of baseline for the both) without affecting LVDP. Prior rhEPO treatment significantly prevented doxorubicin-induced deleterious effects on LVDP, EDP, and VT/VF incidence. rhEPO administration also prevented trastuzumab-induced deleterious effects on CPP and EDP. This study shows that pretreatment by rhEPO protects myocardium against functional damage and electrophysiologic injury induced by acute doxorubicin or trastuzumab exposure. Further investigations are required to elucidate the precise mechanisms involved.

Key Words: erythropoietin • doxorubicin • trastuzumab • cardiotoxicity • isolated rat heart






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Experimental Biology and Medicine.